Strongbridge Biopharma plc
SBBP · NASDAQ
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Revenue | $30,731 | $21,712 | $18,027 | $7,046 |
| % Growth | 41.5% | 20.4% | 155.8% | – |
| Cost of Goods Sold | $2,212 | $3,822 | $3,986 | $1,483 |
| Gross Profit | $28,519 | $17,890 | $14,041 | $5,563 |
| % Margin | 92.8% | 82.4% | 77.9% | 79% |
| R&D Expenses | $25,795 | $30,903 | $25,441 | $17,268 |
| G&A Expenses | $40,867 | $45,810 | $63,336 | $36,292 |
| SG&A Expenses | $40,867 | $45,810 | $63,336 | $36,292 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5,022 | $5,022 | $7,187 | $5,022 |
| Operating Expenses | $71,684 | $81,735 | $95,964 | $58,582 |
| Operating Income | -$43,165 | -$63,845 | -$81,923 | -$53,019 |
| % Margin | -140.5% | -294.1% | -454.4% | -752.5% |
| Other Income/Exp. Net | -$1,925 | $16,162 | $114,310 | -$58,693 |
| Pre-Tax Income | -$45,090 | -$47,683 | $32,387 | -$111,712 |
| Tax Expense | -$15 | $1,768 | $536 | $1,771 |
| Net Income | -$45,075 | -$49,451 | $31,851 | -$113,483 |
| % Margin | -146.7% | -227.8% | 176.7% | -1,610.6% |
| EPS | -0.8 | -0.89 | 0.64 | -3.11 |
| % Growth | 10.1% | -239.1% | 120.6% | – |
| EPS Diluted | -0.8 | -0.89 | 0.64 | -3.11 |
| Weighted Avg Shares Out | 56,105 | 55,383 | 49,725 | 36,545 |
| Weighted Avg Shares Out Dil | 56,105 | 55,383 | 49,725 | 36,545 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,336 | $0 | $12,515 | $4,313 |
| Depreciation & Amortization | $5,107 | $5,099 | $7,233 | $5,032 |
| EBITDA | -$38,647 | -$42,584 | $52,135 | -$102,367 |
| % Margin | -125.8% | -196.1% | 289.2% | -1,452.8% |